ERBB2 and neoplasm: In this study, we have developed NIR-activable triple-receptor-targeted photoimmuno-nanoconjugates (TR-PINs) with three ligands, conjugated to a single photosensitizing nanoconstruct to simultaneously target heterogeneous tumor cell subpopulations with differential expression levels of EGFR, TfR, and HER-2.